Back to Journals » Drug Design, Development and Therapy » Volume 13

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

Total article views   HTML views PDF downloads Totals
9,211 Dovepress* 7,989+ 1,220 9,209
PubMed Central* 1,222 282 1,504
Totals 9,211 1,502 10,713
*Since 29 March 2019
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar